Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 4;7(11):e2447644.
doi: 10.1001/jamanetworkopen.2024.47644.

Alcohol Use and Antiobesity Medication Treatment

Lisa R Miller-Matero  1   2 , Hsueh-Han Yeh  1 , Lisiyu Ma  1 , Rebecca A Jones  3 , Spencer Nadolsky  3 , Adam Medcalf  3 , Gary D Foster  3   4 , Michelle I Cardel  3   5   6
Affiliations

Alcohol Use and Antiobesity Medication Treatment

Lisa R Miller-Matero et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study examines the association of antiobesity medication use and alcohol use among participants enrolled in a weigh loss program.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Jones, Nadolsky, Foster, and Cardel and Mr Medcalf reported serving as employees of and owning stock in WW International during the conduct of the study. No other disclosures were reported.

References

    1. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821-2839. doi:10.1007/s12325-021-01710-0 - DOI - PMC - PubMed
    1. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. doi:10.1038/s41467-024-48780-6 - DOI - PMC - PubMed
    1. Ard J, Hong YR, Foster G, Medcalf A, Nadolsky S, Cardel M. Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment provider. Research Square. Preprint posted online March 5, 2024. doi:10.21203/rs.3.rs-3959336/v1 - DOI - PMC - PubMed
    1. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293. doi:10.1111/j.1360-0443.2012.04054.x - DOI - PMC - PubMed
    1. Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625-641. doi:10.1111/bph.15677 - DOI - PMC - PubMed

LinkOut - more resources